Trial Profile
A Phase I Study of Metronomic Temozolomide and Intravenous Ascorbic Acid for Patients With Recurrent High Grade Glioma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 28 Nov 2023
Price :
$35
*
At a glance
- Drugs Ascorbic acid (Primary) ; Temozolomide (Primary)
- Indications Glioma
- Focus Adverse reactions
- 03 Dec 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov
- 04 Jul 2014 New trial record